Public list Pharma Startups (4733):
Protez Pharmaceuticals entered a 20-site Phase II human clinical trial in 2008 with its lead compound, PZ-601, a antibiotic candidate focused on drug resistance in difficult to treat infections.
30 Spring Mill Drive
Pennsylvania, United States
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)